Rochester, Minn.-based Mayo Clinic researchers analyzed data from 22,000 clinical trial participants, following those with and without low ejection fraction. They simulated the long-term progression of low ejection fraction, assigning values for health burden and economic effect, according to a Dec. 4 news release from Mayo Clinic.
“We categorized patients as either AI-ECG positive, meaning we would recommend further testing for low ejection fraction, or AI-ECG negative with no further tests needed. Then we followed the normal path of care and looked at what that would cost,” Xiaoxi Yao, PhD, professor of health services research at Mayo Clinic and senior author of the study, said in the release.
The use of AI-powered ECG also resulted in a $1,651 cost-effectiveness ratio per quality-adjusted life year in outpatient settings.
Read the full study here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
